Seasonal Flu Diagnostic Elisa Kit 2017

Lab Reagents

Human IgG antibody Laboratories manufactures the seasonal flu diagnostic elisa kit 2017 reagents distributed by Genprice. The Seasonal Flu Diagnostic Elisa Kit 2017 reagent is RUO (Research Use Only) to test human serum or cell culture lab samples. To purchase these products, for the MSDS, Data Sheet, protocol, storage conditions/temperature or for the concentration, please contact influenza elisa. Other Seasonal products are available in stock. Specificity: Seasonal Category: Flu Group: Diagnostic Elisa

Diagnostic Elisa information

Human Influenza viruses IgG,FLU ELISA Kit
201-12-1767 96 tests
EUR 528
Description: A quantitative ELISA kit for measuring Human in samples from biological fluids.

Human Influenza viruses IgG(FLU)ELISA Kit
GA-E1783HM-48T 48T
EUR 346.8

Human Influenza viruses IgG(FLU)ELISA Kit
GA-E1783HM-96T 96T
EUR 559.2

Human Influenza viruses IgG(FLU)ELISA Kit
QY-E02255 96T
EUR 433.2

Custom Antibody titration by ELISA up to 2 rabbits and 1 bleed
ELISA-1 1
EUR 242.4

Human Influenza viruses A,FLU A ELISA Kit
201-12-1596 96 tests
EUR 528
Description: A quantitative ELISA kit for measuring Human in samples from biological fluids.

Human Influenza viruses B,FLU B ELISA Kit
201-12-2058 96 tests
EUR 528
Description: A quantitative ELISA kit for measuring Human in samples from biological fluids.

Human Influenza viruses A(FLU A)ELISA Kit
GA-E1612HM-48T 48T
EUR 346.8

Human Influenza viruses A(FLU A)ELISA Kit
GA-E1612HM-96T 96T
EUR 559.2

Human Influenza viruses B(FLU B)ELISA Kit
QY-E02256 96T
EUR 433.2

Human Influenza viruses A(FLU A)ELISA Kit
QY-E02257 96T
EUR 433.2

Seasonal H1N1 Hemagglutinin Antibody
5231-002mg 0.02 mg
EUR 206.18
Description: Seasonal H1N1 Hemagglutinin Antibody: Influenza A virus is a major public health threat, killing more than 30, 000 people per year in the USA. In early 2009, a novel swine-origin influenza A (H1N1) virus was identified in specimens obtained from patients in Mexico and the United States. The virus spread quickly around the world and on June 11, 2009, the World Health Organization declared it a pandemic. Influenza A virus has one of sixteen possible Hemagglutinin (HA) surface proteins and one of nine possible Neuraminidase (NA) surface proteins. The Hemagglutinin protein facilitates viral attachment while Neuraminidase is involved in viral release. These proteins also elicit immune responses that prevent infection or independently reduce viral replication. The genetic make-up of this swine flu virus is unlike any other: it is an H1N1 strain that combines a triple assortment first identified in 1998 including human, swine, and avian influenza with two new pig H3N2 virus genes from Eurasia, themselves of recent human origin. The distinct antigenic properties of the new swine virus compared with seasonal influenza A (H1N1) virus suggest that human immunity against new swine influenza virus is limited, although the age distribution of reported cases suggests some degree of protection in older age groups.

Seasonal H1N1 Hemagglutinin Antibody
5231-01mg 0.1 mg
EUR 523.7
Description: Seasonal H1N1 Hemagglutinin Antibody: Influenza A virus is a major public health threat, killing more than 30, 000 people per year in the USA. In early 2009, a novel swine-origin influenza A (H1N1) virus was identified in specimens obtained from patients in Mexico and the United States. The virus spread quickly around the world and on June 11, 2009, the World Health Organization declared it a pandemic. Influenza A virus has one of sixteen possible Hemagglutinin (HA) surface proteins and one of nine possible Neuraminidase (NA) surface proteins. The Hemagglutinin protein facilitates viral attachment while Neuraminidase is involved in viral release. These proteins also elicit immune responses that prevent infection or independently reduce viral replication. The genetic make-up of this swine flu virus is unlike any other: it is an H1N1 strain that combines a triple assortment first identified in 1998 including human, swine, and avian influenza with two new pig H3N2 virus genes from Eurasia, themselves of recent human origin. The distinct antigenic properties of the new swine virus compared with seasonal influenza A (H1N1) virus suggest that human immunity against new swine influenza virus is limited, although the age distribution of reported cases suggests some degree of protection in older age groups.

Seasonal H1N1 Hemagglutinin Peptide
5231P 0.05 mg
EUR 197.7
Description: Seasonal H1N1 Hemagglutinin peptide

Seasonal H1N1 Hemagglutinin Antibody
5235-002mg 0.02 mg
EUR 206.18
Description: Seasonal H1N1 Hemagglutinin Antibody: Influenza A virus is a major public health threat, killing more than 30,000 people per year in the USA. In early 2009, a novel swine-origin influenza A (H1N1) virus was identified in specimens obtained from patients in Mexico and the United States. The virus spread quickly around the world and on June 11, 2009, the World Health Organization declared it a pandemic. Influenza A virus has one of sixteen possible Hemagglutinin (HA) surface proteins and one of nine possible Neuraminidase (NA) surface proteins. The Hemagglutinin protein facilitates viral attachment while Neuraminidase is involved in viral release. These proteins also elicit immune responses that prevent infection or independently reduce viral replication. The genetic make-up of this swine flu virus is unlike any other: it is an H1N1 strain that combines a triple assortment first identified in 1998 including human, swine, and avian influenza with two new pig H3N2 virus genes from Eurasia, themselves of recent human origin. The distinct antigenic properties of the new swine virus compared with seasonal influenza A (H1N1) virus suggest that human immunity against new swine influenza virus is limited, although the age distribution of reported cases suggests some degree of protection in older age groups.

Seasonal H1N1 Hemagglutinin Antibody
5235-01mg 0.1 mg
EUR 523.7
Description: Seasonal H1N1 Hemagglutinin Antibody: Influenza A virus is a major public health threat, killing more than 30,000 people per year in the USA. In early 2009, a novel swine-origin influenza A (H1N1) virus was identified in specimens obtained from patients in Mexico and the United States. The virus spread quickly around the world and on June 11, 2009, the World Health Organization declared it a pandemic. Influenza A virus has one of sixteen possible Hemagglutinin (HA) surface proteins and one of nine possible Neuraminidase (NA) surface proteins. The Hemagglutinin protein facilitates viral attachment while Neuraminidase is involved in viral release. These proteins also elicit immune responses that prevent infection or independently reduce viral replication. The genetic make-up of this swine flu virus is unlike any other: it is an H1N1 strain that combines a triple assortment first identified in 1998 including human, swine, and avian influenza with two new pig H3N2 virus genes from Eurasia, themselves of recent human origin. The distinct antigenic properties of the new swine virus compared with seasonal influenza A (H1N1) virus suggest that human immunity against new swine influenza virus is limited, although the age distribution of reported cases suggests some degree of protection in older age groups.

Seasonal H1N1 Hemagglutinin Peptide
5235P 0.05 mg
EUR 197.7
Description: Seasonal H1N1 Hemagglutinin peptide